Forbion

Forbion is a Netherlands-based global venture capital firm focused on life sciences, with offices in Naarden (NL), Munich (DE), and Boston (MA). Founded in 2000 as ABN AMRO Capital Life Sciences and rebranded to Forbion Capital Partners in 2006 (shortened to Forbion in 2018), the firm manages approximately €5 billion across eleven funds. It operates four investment strategies: Forbion Ventures (pre-clinical to early clinical-stage biotech, Series A–B focus; current fund: Forbion Ventures VII at €890m, closed October 2024); Forbion Growth (private growth capital, crossovers, and public investments for clinical-stage companies; current fund: Forbion Growth Opportunities III at €1.2bn, closed October 2024); Forbion Formation (a joint venture with BioGeneration Ventures covering pre-seed/seed/early-stage in Benelux and Germany); and Forbion BioEconomy (Series A+ investments in food, agriculture, materials, and environmental technologies). As of Sep 2026, the firm has made 128+ investments across its fund history, with a primary geographic focus on Europe and selective investments in North America.